Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05261321 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure

Study acronym: CAPU RISE
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2024 to Mar 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Eligibility criteria expanded, about 11 words
    • Site details revised
    v5
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
    • Enrollment target: 12 to 20
    • Start date changed from estimate of Nov 2022 to Oct 15, 2022
    • Eligibility criteria shortened, about 51 words
    • Site details revised
    • Study description shortened, about 4 words
  3. Start date: Jun 2022 to Nov 2022
    • Eligibility criteria shortened, about 157 words
    • Study description shortened, about 8 words
    v3
  4. Start date: Mar 2022 to Jun 2022v2 Show 4 more changesShow less
    • Primary endpoints: 2 to 4
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: 6 to 5
    • Study description revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this Phase I non-therapeutic trial is to examine the neurological effects of cannabis on stress reactivity and inhibition in healthy cannabis users. We expect differences between high ratio CBD:THC cannabis oil, low ratio CBD:THC cannabis oil, and/or placebo on outcome measures.
Trial Details
NCT Number NCT05261321
Lead Sponsor University of British Columbia
Conditions
(from sponsor)		 Healthy
Related terms Marijuana Abuse
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov